Monoamine Oxidase Inhibitors as Anti-Depressant Drugs and as Adjunct to L-Dopa Therapy of Parkinson’s Disease
Monoamine oxidase inhibitors have been used in Psychiatric disorders for many years. However, due to the toxic side effects of the drugs they are often replaced by the tri- and tetracyclic antidepressants.
Selective monoamine oxidase inhibitors like deprenyl, however, have been tried with success as adjuvant therapy in Parkinson’s disease and depression because of their ability to inhibit dopamine oxidation. Perhaps their greatest advantage is their lack of pressor response.
KeywordsMental Disease Monoamine Oxidase Depressive Illness Hypertensive Crisis Tetracyclic Antidepressant
Unable to display preview. Download preview PDF.
- Birkmayer, W., Riederer, P., Youdim, M. B. H.: Deprenyl and Parkinson’s disease. In: Clinical Neuropharmacology (Klawans, H., ed.). New York: Raven Press. In press.Google Scholar
- Einberg, J., Sabbagh, A., Youdim, M. B. H.: Pharmacology of selective acetylenic suicide inhibitors of monoamine oxidase. In: Enzymes and Neurotransmitters in Mental Disease (Usdin, E., Sourkes, T. L., Youdim, M. B. H., eds.). London: J. Wiley. In press (1980).Google Scholar
- Green, A. R., Mitchell, B., Tordoff, A., Youdim, M. B. H.: Evidence for dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of inhibition of enzyme necessary for increased functional activity of dopamine and 5-hydroxytrypt- amine. Brit. J. Pharmacol. 60, 343–349 (1977).Google Scholar
- Green, A. R., Youdim, M. B. H.: Effects of monoamine oxidase inhibition by clorgyline, deprenyl or tranylcypromine on 5-hydroxytryptamineconcentration in rat brain and hyperactivity following tryptophan administration. Brit. J. Pharmacol. 55, 415–422 (1975).Google Scholar
- Lees, A. J., Shaw, K. M., Kohout, L. J., Stern, G. Af., Eisworth, J. D., Sandler, Af., Youdim, Äf..: Deprenyl in Parkinson’s disease. Lancet 2, 791–796 (1977).Google Scholar
- Youdim, M. B. H.: The use of selective monoamine oxidase “type B” inhibitors in the treatment of Parkinson’s disease. In: Enzymes and Neurotransmitters in Mental Disease (Usdin, E., Sourkes, T. L., Youdim, M. B. H., eds.). London: J. Wiley. In press (1980).Google Scholar
- Youdim, M. B. H., Collins, G. G., Sandler, M.: Monoamine oxidase: Multiple forms and selective inhibition. Biochem. J. 121, 34–36 (1971).Google Scholar
- Youdim, M. B. H., Green, A. R., Grahame-Smith, D. GThe role of 5-hydroxytryptamine, dopamine and MAO in the production of hyperactivity Syndrome. In: Advances in Parkinsonism (Birkmayer, W., Hornykiewicz, O., eds.), pp. 155–162. Basle: Editiones Roche. 1976.Google Scholar
- Youdim, M. B. H., Mendlewicz, J.; Monoamine oxidase inhibition without the “cheese effect”: Clinical and pharmacological relevance in the treatment of depression. In: Enzymes and Neurotransmitters in Mental Disease (Usdin, E., Sourkes, T. L., Youdim, M. B. H., eds.). London: J. Wiley. In press (1980).Google Scholar